What does the US FDA approval of Anktiva® signify for bladder cancer care?

The US FDA recently approved Anktiva® (N-803), a first-of-its-kind immunotherapy, in combination with BCG for the treatment of non-muscle-invasive bladder cancer (NMIBC). In this interview, we speak with Karim Chamie (UCLA, CA, USA) to discover the importance of IL-15 in NMIBC and how this links with Anktiva’s mechanism of action. Chamie also provides a bitesize breakdown of key results from the QUILT 3.032 study, which is evaluating its efficacy and safety. What are the current treatment options for non-muscle-invasive bladder cancer? Current treatment options for NMIBC include surgery to remove the tumors, followed by treatment with Bacillus Calmette-Guerin (BCG) and...